Clinical trials: Secondary Hyperparathyroidism Due to Renal Causes
Secondary Hyperparathyroidism Due to Renal Causes
Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy
In this study, investigators measure patient's voice frequency, swallowing function, and O2 desaturation of the 6 mins walking test before surgery and 4 months after surgery, to find the increase of voice frequency, and…
- Trial name
- NCT04267965
- Testing
- parathyroidectomy plus bilateral thymectomy and autotransplantation
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Chang Gung Memorial Hospital
Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in…
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Trial name
- NCT03588884
- Testing
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol
- Where
- 3 sites in United States
- Volunteers
- 69 people
- Sponsor
- OPKO Health, Inc.
Secondary Hyperparathyroidism Due to Renal Causes, End Stage Renal Failure
Retrospective Analysis of Quality of Life Changes in Patients Undergoing Parathyroidectomy for End-Stage Renal Disease
The purpose of this study is to characterize changes in quality of life in patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease, based on data extracted from an established…
- Trial name
- NCT07151664
- Testing
- Quality of life progression after parathyroidectomy
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to…
- Conditions
- Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Deficiency
- Trial name
- NCT05549154
- Testing
- High-dose vitamin D2 softgels, low-dose vitamin D2 softgels
- Where
- China
- Volunteers
- 372 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Secondary Hyperparathyroidism Due to Renal Causes
Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.
To demonstrate the superiority of paricalcitol treatment at early renal post-transplantation (M6) in the control of iPTH (Intact parathyroid hormone) compared to the use of vitamin D nutritional supplements (calcifediol) in…
- Trial name
- PARIDOINAL (NCT01939977)
- Testing
- Paricalcitol, Calcifediol
- Where
- 16 sites in Spain
- Volunteers
- 148 people
- Sponsor
- Fundación Senefro